Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology

SIMPLE SUMMARY: About 20% of patients with cancer who participate in a phase I clinical trial discontinue the trial early. Early trial discontinuation is undesirable both for the wellbeing of the patient as well as for the trial efficiency and the development of new anticancer drugs. We investigated...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancers (Basel)
Asıl Yazarlar: Douma, Joeri A. J., Buffart, Laurien M., Sedhom, Ramy, Labots, Mariette, Menke-van der Houven van Oordt, Willemien C., Skardhamar, Mikkjal, De Felice, Anthony, Lee, Esther, Dharmaraj, Divya, Azad, Nilofer S., Carducci, Michael A., Verheul, Henk M. W.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI 2021
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8151105/
https://ncbi.nlm.nih.gov/pubmed/34064995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13102304
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller